Previous 10 | Next 10 |
Osmotica Pharmaceuticals (OSMT): Q4 GAAP EPS of -$0.88 misses by $0.64.Revenue of $34.53M (-42.4% Y/Y) misses by $1.2M.Strengthened balance sheet by reducing $50 million in debt and increasing cash.Press Release For further details see: Osmotica Pharmaceuticals EPS misses by $0.64, miss...
Fourth quarter and full year 2020 total revenue of $34.5 million and $177.9 million, respectively Received FDA approval and subsequently introduced Upneeq ® (oxymetazoline hydrochloride ophthalmic solution, 0.1%), the first therapeutic for treatment of acquired ptosis i...
BRIDGEWATER, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 fourth quarter and full year fina...
BRIDGEWATER, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief ...
BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief F...
BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- fAp9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRIS...
BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ap9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRI...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE January 27, 2021 Osmotica Pharmaceuticals...
Shares of Osmotica Pharmaceuticals (NASDAQ: OSMT) , a biopharmaceutical company, dropped by as much as 24.4% on Wednesday and closed today's trading session down by 20%. Investors sold off shares of the company following its announcement that the U.S. Food and Drug Administration (F...
Gainers: Professional Diversity Network (IPDN) +118%.SGOCO Group (SGOC) +85%.Bionano Genomics (BNGO) +84%.Net Element (NETE) +51%.Conifer Holdings (CNFR) +45%.Guardion Health Sciences (GHSI) +41%.Indonesia Energy Corporation (INDO) +40%.IKONICS Corporation (IKNX) +35%.Bit Digital (BTBT) ...
News, Short Squeeze, Breakout and More Instantly...
Osmotica Pharmaceuticals plc Company Name:
OSMT Stock Symbol:
NASDAQ Market:
Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities RVL Pharmaceuticals plc Ordinary Shares Expected to be Cancelled in 2024 BRIDGEWATER, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals, I...
Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected t...
BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 inve...